PAVM
PAVmed Inc

8,822
Mkt Cap
$9.44M
Volume
744,075.00
52W High
$1.25
52W Low
$0.304
PE Ratio
-0.56
PAVM Fundamentals
Price
$0.32
Prev Close
$0.3537
Open
$0.36
50D MA
$0.4304
Beta
1.35
Avg. Volume
706,680.39
EPS (Annual)
$0.4961
P/B
0.87
Rev/Employee
$76,794.87
Loading...
Loading...
News
all
press releases
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum
Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and Digital Health & Services Forum Lucid Diagnostics to Participate in the Canaccord Genuity MedTech, Diagnostics and...
PR Newswire·2d ago
News Placeholder
More News
News Placeholder
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results
PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results PAVmed Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire NEW YORK, Nov. 13, 2025...
PR Newswire·2d ago
News Placeholder
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results
Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results Lucid Diagnostics Provides Business Update and Reports Third Quarter 2025 Financial Results PR Newswire NEW...
PR Newswire·3d ago
News Placeholder
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025
PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025 PAVmed to Hold a Business Update Conference Call and Webcast on November 13, 2025 PR Newswire NEW YORK, Oct. 30, 2025...
PR Newswire·16d ago
News Placeholder
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025
Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025 Lucid Diagnostics to Hold a Business Update Conference Call and Webcast on November 12, 2025 PR Newswire...
PR Newswire·17d ago
News Placeholder
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit
Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit Lucid Diagnostics to Participate in the 2025 Maxim Growth Summit PR Newswire NEW YORK, Oct. 15, 2025 NEW YORK, Oct. 15, 2025...
PR Newswire·1mo ago
News Placeholder
PAVmed (PAVM) Upgraded to Strong Buy: Here's Why
PAVmed (PAVM) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
Zacks·1mo ago
News Placeholder
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement
Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement Lucid Diagnostics Regains Compliance with Nasdaq Minimum Bid Price Requirement PR Newswire NEW YORK, Feb. 25, 2025 NEW...
PR Newswire·9mo ago
News Placeholder
PAVmed and Subsidiary Veris Health Complete Private Placement Financing
PAVmed and Subsidiary Veris Health Complete Private Placement Financing PAVmed and Subsidiary Veris Health Complete Private Placement Financing PR Newswire NEW YORK, Feb. 24, 2025 Gross proceeds of...
PR Newswire·9mo ago
News Placeholder
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health
Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health Lucid Diagnostics Executes First Concierge Medicine Contract with LEAA Health PR Newswire NEW YORK, Feb. 20, 2025 LEAA...
PR Newswire·9mo ago

Latest PAVM News

View

Advertisement|Remove ads.

Advertisement|Remove ads.